Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ries Kranse

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The Canadian Journal of Urology|June 21, 2013
Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier methodXiaoye Zhu, Ries Kranse, Meelan Bul, et al.
European Urology|January 31, 2006
Does PSA velocity predict prostate cancer in pre-screened populations?Fritz H Schröder, Monique J Roobol, Theo H van der Kwast, et al.
Cancer|November 17, 2006
Metastatic disease of screen-detected prostate cancer : characteristics at diagnosisStijn Roemeling, Ries Kranse, André N Vis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 15, 2014
Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancerWillemien Beukers, Raju Kandimalla, Roy G Masius, et al.
Diseases of the Colon and Rectum|April 20, 2012
The incidence and risk factors of metachronous colorectal cancer: an indication for follow-upSanna A Mulder, Ries Kranse, Ronald A Damhuis, et al.
Journal of Medical Screening|January 25, 2011
Disease-specific mortality may underestimate the total effect of prostate cancer screeningPim J van Leeuwen, Ries Kranse, Timo Hakulinen, et al.
European Urology|September 8, 2009
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancerMonique J Roobol, Ewout W Steyerberg, Ries Kranse, et al.
Cancer|September 15, 2010
Balancing the harms and benefits of early detection of prostate cancerPim J van Leeuwen, David Connolly, Teuvo L J Tammela, et al.
BJU International|February 1, 2012
Increased non-prostate cancer death risk in clinically diagnosed prostate cancerPim J van Leeuwen, Suzie J Otto, Ries Kranse, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2011
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progressionCaroline Schroten, Natasja F Dits, Ewout W Steyerberg, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Canadian Journal of Urology|June 21, 2013
Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier methodXiaoye Zhu, Ries Kranse, Meelan Bul, et al.
European Urology|January 31, 2006
Does PSA velocity predict prostate cancer in pre-screened populations?Fritz H Schröder, Monique J Roobol, Theo H van der Kwast, et al.
Cancer|November 17, 2006
Metastatic disease of screen-detected prostate cancer : characteristics at diagnosisStijn Roemeling, Ries Kranse, André N Vis, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 15, 2014
Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancerWillemien Beukers, Raju Kandimalla, Roy G Masius, et al.
Diseases of the Colon and Rectum|April 20, 2012
The incidence and risk factors of metachronous colorectal cancer: an indication for follow-upSanna A Mulder, Ries Kranse, Ronald A Damhuis, et al.
Journal of Medical Screening|January 25, 2011
Disease-specific mortality may underestimate the total effect of prostate cancer screeningPim J van Leeuwen, Ries Kranse, Timo Hakulinen, et al.
European Urology|September 8, 2009
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancerMonique J Roobol, Ewout W Steyerberg, Ries Kranse, et al.
Cancer|September 15, 2010
Balancing the harms and benefits of early detection of prostate cancerPim J van Leeuwen, David Connolly, Teuvo L J Tammela, et al.
BJU International|February 1, 2012
Increased non-prostate cancer death risk in clinically diagnosed prostate cancerPim J van Leeuwen, Suzie J Otto, Ries Kranse, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2011
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progressionCaroline Schroten, Natasja F Dits, Ewout W Steyerberg, et al.
Pageof 4